Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
BIOTECHNOLOGY Unprecedented Growth & Future Job Opportunity Dr. Sanjiv Kumar Maheshwari Professor and Dean, IFTM University, Moradabad Biotechnology Market and Growth Potential Players Opportunities Why India Courses offered by School of Biotechnology, IFTM University S No Course 1 B. Tech. (Biotechnology) 2 Duration (Years) Fee Per semester (RS.) Eligibility 45000 Minimum 45% (40% for SC/ST) at 10+2 with Physics, Chemistry, Mathematics / Biology B. Sc. 3 (Biotechnology/Microbiology /Food Technology) 20000 Minimum 45% (40% for SC/ST) at 10+2 with Physics, Chemistry, Mathematics / Biology 3 M. Sc. 2 (Biotechnology/Microbiology /Food Technology) 18000 Minimum 50% (45% for SC/ST) at B.Sc. (Biotech.) / related Life Sciences 4 M. Tech. (Biotechnology) 2 41000 Minimum 55% at B. Tech. (Biotechnology) 5 Ph. D. (Biotechnology) 2 30000 As per latest UGC Norms 4 Biotech Market - Dynamic and growing US$ 1 BN= 634 Crore Size (2004-05) US$ 1090.5 mn Size (2010-11) US$ 4 Bn Largest segment Biopharma not to be confused with Pharma Revenue from exports (2010-11) 56% Growth of Sector (2011-12) over 50% Total investment (2003-04) Rate of growth over 202-2003 US$ 137 million 26% Biopharma leads the way Composition of Indian Biotech Sector (2004-05) Bio Agri Bio-IT 6.95% 2.09 % Bio Industrial 6.74% Bio Services 8.95% Bio Pharma 75.24 % Source:Biospectrum-ABLE Survey Biotechnology as a Sector Third Largest Biotech Industry in Asia Pacific Region. Second Highest number of USFDA approved plants. US$ 3.7 BN to be spent on Biotechnology in India from 201217. No. 1 producer of Hepatitis B Vaccine. US$ 4.3 BN Bioeconomy (earning from Biotechnology) by the end of 2015 US$ 200 BN Industry by 2025. US$ 1 BN= 634 Crore (Source: Make in India) Market - A consistent uptrend 25% growth in investment 2002-03 70% growth in employment 74% growth in R&D manpower US$ 5 billion annual revenues 2010 1 million skilled jobs 10% of global industry Source: Confederation of Indian Industry (CII) Indian Players MNCs Scripting Success in India Top MNCs World Wide Market Cap in Q2 2015 Market Cap in 2014 (USD billion (USD billions USA Switzerland Switzerland USA USA DEN USA FRA USA USA GBR USA USA USA USA GBR USA USA 276.9 272.6 240.4 211.7 162.3 147.0 145.1 136.0 117.7 116.7 114.1 105.0 97.0 91.7 90.4 87.7 79.2 69.9 277.8 229.8 258.5 205.4 166.9 125.4 109.0 138.1 93.1 38.2 128.9 97.6 79.7 104.1 89.5 88.9 76.6 67.9 Valeant Pharmaceuticals CAN 67.7 47.9 Teva Pharmaceutical ISR 54.5 49.0 Rank Company Country 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Johnson & Johnson Novartis Roche Pfizer Merck Novo Nordisk Gilead Sciences Sanofi Amgen Actavis GlaxoSmithKline Bristol-Myers Squibb Biogen Idec AbbVie Celgene AstraZeneca Eli Lilly & Co Abbott Laboratories 19 20 India: The Vaccine Hub Indian firms estimated to supply 90% of global demand for the measles vaccine, in the near future. Serum Institute, Pune is believed to be the world`s largest manufacturer of DPT vaccines. Indian Immunologicals operates the world`s second largest plant for veterinary vaccines and is also the world`s largest manufacturer of the vaccine against Foot and Mouth Disease. Invest in Agri Biotech Ag. Biotechnology Biofertilisers GM Crops and seeds Biofuels Biopesticides The India Advantage Excellent network of research laboratories Rich biodiversity Well-developed base industries Extensive clinical trials opportunities Trained manpower and knowledge base The R & D Advantage Genetic Engineering Biotech R&D strengths spread across range of segments DNA technologies New Drug Delivery Systems Rational drug design Stem cell research Bioinformatics